EN
ENEnglishDEDeutschESEspañolFRFrançaisITItalianoELΕλληνικά
Login

Literature ·

Empagliflozin and Major Renal Outcomes in Heart Failure.

Milton Packer, Javed Butler, Faiez Zannad et al. · The New England journal of medicine

This EMPEROR-Reduced renal analysis showed that empagliflozin slowed the decline in eGFR and reduced the risk of serious kidney outcomes in patients with heart failure, demonstrating renoprotective effects of SGLT2 inhibition in the heart failure population.

Source

Join us

Join the Global Primary Care Cardio Network. Membership is free.

Would you like to tell us more about yourself?

Interests

We will send you an email with a link to confirm your registration.

More on Diabetes

11 min

Cardiorenal risk management in Primary care: Panel Discussion

11 min

Optimising Management with SGLT-2i-based Strategies in Primary Care

· Dr Sarah Davies, General Practitioner, Woodlands Medical…9 min

The Foundation of Cardiorenal Protection: What the Guidelines Say

· Dr Ileana Pina, Thomas Jefferson University, Philadelphia…
CKD; New ESC Guidelines: Every Patient with Heart Disease Should Now Be Tested for Kidney DiseaseGlobal guideline on the use of GLP-1 medicines in treating obesity issued by WHOEU Launches Ambitious "Safe Hearts Plan": A New Roadmap in Cardiovascular HealthEz-PAVE, second randomisationSodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and ErythropoiesisEffect of Obicetrapib on Glycaemia and New-Onset DiabetesFinerenone